All In Biotech

Drug Trial Radar · NCT06897839

Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)

Randomized, Double-Blind Parallel-Group, Adaptive, Three-Arm, Phase 2b/3 Multicenter Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preventing Bronchopulmonary Dysplasia (BPD) in High-Risk Preterm Neonates Compared to Standard of Care (SOC)

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 366 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

366

Planned (sponsor's estimate)

Start

Feb 3, 2025

Primary completion

Mar 31, 2028

Study completion Apr 30, 2030

Sponsor

Lead sponsor
Airway Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 0 minutes, up to 96 hours
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, parallel-group, double-blind, placebo-controlled multicenter phase 2b/3 study with an adaptive seamless design. The goal fo this study is to determine if an investigational drug, Zelpultide Alfa, can reduce the occurrence of Bronchopulmonary Dysplasia (BPD) in extremely premature babies. The study comprises 2 parts: * Part 1: Phase 2b, dose selection and exploratory efficacy and safety. * Part 2: Phase 3, confirmatory efficacy and safety. In Part 1, the study subjects will be randomized with a 1:1:1 allocation ratio to either : 1. Standard of care + zelpultide alfa 4 mg/kg or, 2. Standard of care + zelpultide alfa 6 mg/kg or, 3. Standard of care + placebo (air-sham). In Part 1, all three arms will be evaluated descriptively to support dose selection based on safety, tolerability, and exploratory efficacy signals. Upon completion of Part 1, the DSMC will recommend which Phase 2b dose ("selected dose") to progress into Part 2 to the Study Steering Committee, which will decide the dose for Part 2 (Phase 3). A sample size reassessment will be performed after Part 1 completion. In Part 2, the selected dose of zelpultide alfa will be compared against placebo (air-sham) in a confirmatory analysis on the primary and key secondary endpoints. The study subjects will be randomized with a 1:1 allocation ratio to either: 1. Standard of care + zelpultide alfa (selected dose from Part 1), or 2. Standard of care + placebo (air-sham). The main objective in part 2 is to compare the efficacy of zelpultide alfa added to standard of care versus standard of care plus placebo (air-sham) in terms of incidence of grade 2 and grade 3 bronchopulmonary dysplasia (BPD) and death in neonates at high risk for developing BPD. In both parts, treatment will be administered intratracheally. Participants will receive up to 7 administrations of zelpultide alfa at (4mg/kg or 6 mg/kg) or air-sham in 24 h intervals while the subjects are still intubated per standard of care.

Conditions

  • Bronchopulmonary Dysplasia

Interventions

  • Air-shamOther

    Room air for intratracheal administration

  • Zelpultide alfaDrug

    Reconstituted Zelpultide alfa for intratracheal administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of grade 2 or grade 3 Bronchopulmonary Dysplasia (BPD) or deathTime frame: Week 36 Post Menstrual Age (PMA)

Locations

56 sites in 10 countries. Site status is shown where the registry gives one.

  • Clínica y Maternidad Suizo Argentina

    Buenos Aires, Argentina · Recruiting

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina · Recruiting

  • Hospital Sanatorio de la Trinidad San Isidro

    Buenos Aires, Argentina · Recruiting

  • Hospital Universitario Austral

    Buenos Aires, Argentina · Recruiting

  • ZAS Middelheim

    Antwerp, Belgium · Recruiting

  • UZ Brussels

    Brussels, Belgium · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • CHU de Liege - Hospital de la Citadelle

    Liège, Belgium · Recruiting

  • Clinique CHC MontLégia

    Liège, Belgium · Recruiting

  • Institute for the Care of Mother and Child

    Prague, Czechia · Not yet recruiting

  • Tomas Bata Regional Hospital in Zlin

    Zlín, Czechia · Not yet recruiting

  • CHU Lille - Hôpital Jeanne de Flandre

    Lille, France · Recruiting

  • CHRU Nancy

    Nancy, France · Recruiting

  • CHU Nice

    Nice, France · Recruiting

  • AP-HP CHU Robert-Debré - Hôpitaux de Paris

    Paris, France · Recruiting

  • AP-HP Paris Saclay University - Hôpitaux Antoine-Béclère

    Paris, France · Recruiting

  • AP-HP Paris Saclay University Bicêtre Hospital

    Paris, France · Recruiting

  • AP-HP University Hospital Cochin - Port Royal

    Paris, France · Recruiting

  • Hôpital de Poissy Saint-Germain-en-Laye

    Poissy, France · Recruiting

  • Medical Faculty of TU Dresden

    Dresden, Germany · Not yet recruiting

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, Germany · Recruiting

  • Heidelberg University Hospital

    Heidelberg, Germany · Not yet recruiting

  • Klinikum Nürnberg

    Nuremberg, Germany · Not yet recruiting

  • University Children's Hospital Regensburg (KUNO)

    Regensburg, Germany · Recruiting

  • University Hospital Würzburg

    Würzburg, Germany · Recruiting

  • Bnai Zion Medical Center

    Haifa, Israel · Recruiting

  • Rambam Medical Center

    Haifa, Israel · Recruiting

  • Haddasah medical center

    Jerusalem, Israel · Recruiting

  • Shaare-Zedek Medical Center

    Jerusalem, Israel · Recruiting

  • Ziv Medical Center

    Safed, Israel · Recruiting

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola

    Bologna, Italy · Recruiting

  • Istituto Giannina Gaslini

    Genova, Italy · Recruiting

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

    Milan, Italy · Recruiting

  • Ospedale dei Bambini "V. Buzzi"

    Milan, Italy · Recruiting

  • Università degli Studi di Napoli Federico II

    Naples, Italy · Recruiting

  • Azienda Ospedale Università di Padova

    Padova, Italy · Recruiting

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, Poland · Recruiting

  • University Hospital in Krakow

    Krakow, Poland · Recruiting

  • Polish Mother's Memorial Hospital - Research Institute in Lodz

    Lodz, Poland · Recruiting

  • Gynecological Obstetric Clinical Hospital of Poznan University of Medical Sciences

    Poznan, Poland · Recruiting

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.